NCT00001797View on ClinicalTrials.gov

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 1999

Study Completion Date

September 30, 2000

Conditions

Psoriasis

Interventions

DRUG

Recombinant human interleukin-10

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00001797 - Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis | Biotech Hunter | Biotech Hunter